Actuate Therapeutics, Inc. Common stock (ACTU)
NasdaqGM
Price as at 30 Sept 2026, 16:02 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Actuate Therapeutics, Inc. Common stock trades at $0.76. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
3 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Travis Cocke, Voss Capital, LP$2.64M · 0.1% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$195.1K · 0.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$147.9K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Which funds own ACTU?
3 of the institutions we track reported a position in ACTU in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its ACTU data?
Fundamentals for ACTU come from company filings and exchange data, as listed on NasdaqGM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 16:02 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for ACTU, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.